We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Pharmacovigilance – News and Features

News

Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory

Pharmatek now offers contract cytotoxic & high- potent analytical, formulation and manufacturing services.
News

Quark Pharmaceuticals Extends Research Agreement with State University of New York

Quark's siRNA compounds for acute hearing loss slated for IND filing by year- end 2007.
News

Abraxis Acquires Exclusive Worldwide Intellectual Property Rights from the Buck Institute

The agreement provides Abraxis with the exclusive property rights for technologies designed to generate therapeutics and identify new drug discovery targets.
News

Quark Pharmaceuticals Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure

Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA.
News

Cell Therapeutics Announces Agreement to Acquire Systems Medicine

Under the terms of the agreement, SMi will continue to operate as a wholly-owned subsidiary of CTI, utilizing its genomic-based platform to guide development of CTI's oncology products.
News

MPI Research Continues Toxicology Expansion

As part of a series of planned expansions, MPI Research announces the immediate availability of additional toxicology capacity.
News

CellCyte Executives Highlight Plans for Breakthrough Stem Cell-Enabling Therapeutic Products and Devices

In an interview published in The Wall Street the executives gave their views about moving quickly into a global leadership position in the emerging field of regenerative medicine with the company's stem cell-enabling therapeutic products and devices.
News

Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin’s Lymphoma Meets Primary Endpoint

Genzyme completes its phase 3 trial of Mozobil™ in non-Hodgkin’s lymphoma, and the trial has robustly met its primary and secondary endpoints.
News

MS Society Announces $2.4M to Continue Ottawa Bone Marrow Stem Cell Transplant Trial

The grant will continue a closely-watched clinical trial involving an experimental bone marrow stem cell transplant therapy at MS Society of Canada.
News

Personalized Medicine: Milestone in the Therapy Control of Humanized Antibodies

CENiMED, BioTeZ and Invitek announce their cooperation to develop, produce and market the Recovery-ELISAs for the therapy control of humanized antibodies.
Advertisement